Original: Bevacizumab is currently approved by the U.S. Food and Drug Administration ( FDA ) for cancers that are metastatic ( have spread to other parts of the body ) . It received its first approval in 2004 for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer .
Simplified: Bevacizumab is an anti-angiogenic drug that is used in the treatment of Metastatic Renal cell carcinoma , Metastatic breast cancer , Non-small cell lung cancer , and is also approved in the treatment Glioblastoma multiforme .